TAILIEUCHUNG - Mesothelioma treatment: Are we on target? A review

Targeted treatment is a therapy directed at a specific molecular target close to a hallmark of cancer. The target should be measurable with a biomarker and measurement of the target should correlate with clinical outcome when targeted treatment is administered. Current clinical guidelines do not recommend targeted or biological therapy in MPM. However, since these recommendations came out, new agents have been investigated in MPM. This review updates the use of targeted and biological treatment in patients with mesothelioma. | Journal of Advanced Research 2015 6 319-330 Cairo University Journal of Advanced Research REVIEW Mesothelioma treatment Are we on target CrossMark A review Birgitta I. Hiddinga Christian Rolfo Jan P. van Meerbeeck Thoracic Oncology MOCA Antwerp University Hospital Belgium GRAPHICAL ABSTRACT ARTICLE INFO ABSTRACT Article history Received 30 August 2014 Received in revised form 8 November 2014 Accepted 23 November 2014 Available online 2 December 2014 Targeted treatment is a therapy directed at a specific molecular target close to a hallmark of cancer. The target should be measurable with a biomarker and measurement of the target should correlate with clinical outcome when targeted treatment is administered. Current clinical guidelines do not recommend targeted or biological therapy in MPM. However since these recommendations came out new agents have been investigated in MPM. This review updates the use of targeted and biological treatment in patients with mesothelioma. 2014 Production and hosting by Elsevier . on behalf of Cairo University. Keywords Malignant pleural mesothelioma Targeted therapy Biological treatment Mesothelin Biomarker Corresponding author. Tel. 32 3 821 45 46. E-mail address . Hiddinga . Peer review under responsibility of Cairo University. Production and hosting by Elsevier http 2090-1232 2014 Production and hosting by Elsevier . on behalf of Cairo University. 320 . Hiddinga et al. Birgitta I. Hiddinga MD is a board certified pulmonologist and completed her training as a chest physician in Enschede the Netherlands. In the University Hospital Ghent Belgium she completed a fellowship in thoracic oncology. She s currently a staff member of the division Thoracic Oncology of Antwerp University Hospital. She s a skilled interventional pulmonologist. Other areas of interest are mesothelioma and neuroendocrine tumours. She is a member of Nederlandse Vereniging voor Longartsen en .

• Y khoa - Dược
• Malignant pleural mesothelioma
• Targeted therapy
• Biological treatment
• Mesothelioma treatment
• Biological therapy in MPM
• BMC Cancer
• Overall survival
• Therapy response
• Chemotherapeutic treatment
• Debilitating disease
• Pleural cavity
• Asbestos fibers
• Multidisciplinary team
• Pleural effusion
• Tumor marker
• Malignant tumor
• Mesothelial origin
• Conventional chemotherapy
• BMC Pulmonary Medicine
• Medical thoracoscopy
• Exudative pleural effusions
• Poor prognosis
• Diagnostic marker
• Enzyme linked immunosorbent assays
• Area under the curve
• MPM diagnosis remains
• Functional measures
• Surgical approach
• Quality of life
• Extrapleural pneumonectomy
• Patient centered care
• Physician requests
• Patient physician communication
• Tumor stroma
• Asbestos exposure
• Fluorescence in situ hybridization
• Palliative care
• Asbestos related diseases
• PD 1 antibody
• Minimal change disease
• Interstitial nephritis
• Lung cancer
• Modelling and simulation
• Computational oncology
• Toxicity balance
• Chemotherapy regimens
• Yielded disease
• Carboplatin plus gemcitabine
• Systemic treatment
• Platinum–based chemotherapy
• Preclinical models
• Reactive oxygen species
• Translational oncology
• Cancer stem cells
• Patient survival
• Aldehyde dehydrogenase
• Malignant mesothelioma
• Pleural effusions
• Primary cells
• Ex vivo chemosensitivity
• Cytotoxic drugs
• Individualized treatment
• Proteasome inhibitor
• Epidermal growth factor receptor
• PI3K/Akt signaling
• Industrialized countries
• MPM incidence
• Chimeric antigen receptor
• Cancer treatment
• Inflammatory cancer
• Emerging avenues
• Checkpoint inhibitors
• Non small cell lung cancer
• Patient derived xenograft
• Ultrasound guided biopsy
• Computerized tomography
• Progression free survival
• Excision repair cross complementation group 1
• Immune related adverse events
• Therapeutic efect
• Immune checkpoint inhibitor
• Contrast enhanced MDCT
• Chest imaging
• Oncologic imaging
• Retrospective study
• Real life experience
• Disease control rate